NCT00411281

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Treatment of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Children's Oncology Group · Network
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing. Giving low-doses of cytarabine may be an effective treatment for Down syndrome and transient myeloproliferative disorder. Sometimes the disease may not need treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase III trial is studying low-dose cytarabine to see how well it works in treating infants with Down syndrome and transient myeloproliferative disorder.

Detailed description

OBJECTIVES: Primary * Determine whether very low-dose cytarabine can improve event-free survival (EFS) rates in infants with high-risk transient myeloproliferative disorder (TMD), using high-risk TMD patients from clinical trial COG-A2971 for historic comparison, and in infants with intermediate-risk TMD, using intermediate-risk TMD patients from clinical trial COG-A2971 for historic comparison. * Maintain the current high overall EFS rate in low-risk TMD patients. Secondary * Assess the toxicity of this regimen in these patients. OUTLINE: This is a nonrandomized, multicenter, crossover study. Patients are stratified according to disease risk (high or intermediate vs low). * Group I (patients with high- or intermediate-risk transient myeloproliferative disorder \[TMD\]): Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation. * Group II (patients with low-risk TMD): Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I. After completion of study treatment, patients are followed periodically for 10 years. PROJECTED ACCRUAL: A total of 180 patients will be accrued for this study.

Conditions

• Leukemia

Interventions

Type	Name	Description
DRUG	cytarabine	Given subcutaneously
PROCEDURE	observation	No intervention

Timeline

• Start date: 2006-03-01
• Primary completion: 2007-11-01
• Completion: 2007-11-01
• First posted: 2006-12-13
• Last updated: 2015-09-30